ABOUT
Neurotechnology Research and Development
Innovative Medical Devices for Alzheimer’s Disease and other Neurological Conditions.
REGEnLIFE is an innovative company founded in 2016 and based in Montpellier. It develops a new therapeutic approach for the prevention and treatment of neurological conditions. Our mission is to offer a technology capable of improving the health and daily lives of patients suffering from debilitating neurological conditions such as Alzheimer's disease. Our technology, called "Tri-Photonic Stimulation," uses biophotonics combined with magnetic fields to limit cognitive decline in patients and slow the progression of the disease.
A team and partners equal to the challenges.
<b>Professionals, experts, engineers, and researchers united in a multidisciplinary dynamic</b>: new technologies, optics, photonics, electronics, physical sciences, public health, medicine, neurology, and neurosciences.
<b>A scientific advisory board chaired by Professor Jacques Touchon</b>, a world expert in Alzheimer's disease.
<b>Internationally recognized partners.</b>
All committed by conviction to the same rigorous approach:
The strict application of a scientific methodology and regulatory requirements in our R&D developments
A quality approach certified according to standard <strong>ISO 13485: 2016.</strong>
A painless, non-invasive, and non-pharmacological technology.
The “Tri-Photonic stimulation,” developed by our Research & Development department, stems from a deep understanding of photobiomodulation parameters. The latter, based on physical sciences, is widely proven in other applications (oncology, dermatology, aesthetics, dental, etc.). Historically developed by NASA for its healing effects, it can finally make its entry and express its full potential in the field of neurology.
